Abstracts tagged "Retroperitoneal Fibrosing and rituximab"

Abstract Number: 370 • 2018 ACR/ARHP Annual Meeting
Rituximab in Idiopathic Retroperitoneal Fibrosis
Veronika Boyeva¹, Hatim Alabsi², Michael Seidman³, Ryan Paterson⁴, Jason Kur⁵, Silvia Chang⁶, Luke Chen⁷ and Mollie Carruthers⁵, ¹Department of Medicine, University of British Columbia, Vancouver, BC, Canada, ²Department of Radiology, King Abdulaziz University, Jeddah, Saudi Arabia, ³Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada, ⁴Department of Urology, University of British Columbia, Vancouver, BC, Canada, ⁵Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁶Department of Radiology, University of British Columbia, Vancouver, BC, Canada, ⁷Department of Hematology, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Retroperitoneal fibrosis (RPF) is a rare disease characterized by the proliferation of fibrous tissue in the retroperitoneum, most commonly surrounding the aorta from the…
Abstract Number: 1175 • 2017 ACR/ARHP Annual Meeting
Rituximab for Idiopathic and IgG4-Related Retroperitoneal Fibrosis
Rachel Wallwork¹, Zachary S. Wallace², Cory A. Perugino³, Amita Sharma⁴ and John H. Stone⁵, ¹Department of Medicine, Massachusetts General Hospital, Boston, MA, ²Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, ⁴Department of Radiology, Massachusetts General Hospital, Boston, MA, ⁵Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Rituximab for Idiopathic and IgG4-Related Retroperitoneal FibrosisBackground/Purpose: Untreated retroperitoneal fibrosis (RPF) can lead to chronic back and flank pain and/or renal failure. The mainstay of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].